News | ACC | March 20, 2018

More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

One-year follow-up results of POISE trial mirror those seen at 30 days

 

More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

ACC late-Breaker 2018 More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease who were treated with the beta blocker metoprolol for 30 days were less likely than patients who received a placebo to have a heart attack, but more likely to die or have a stroke, according to research presented at the American College of Cardiology’s 67th Annual Scientific Session.

These follow-up findings confirm that an increased risk for death or a stroke persists at one year post- surgery in patients treated with metoprolol, said P.J. Devereaux, M.D., Ph.D., director of cardiology at McMaster University in Hamilton, Canada, and lead author of the study. Previously reported results from the same study at 30 days post-surgery showed a similar pattern, with a reduction in heart attacks but increases in deaths and strokes.

“Our results suggest at one year, for every 1,000 patients having noncardiac surgery, treatment with metoprolol would prevent heart attacks in 12 patients but would result in an excess of 13 deaths and six strokes,” Devereaux said.

“While there is little doubt that some patients benefit from receiving beta blockers during the period immediately before and after noncardiac surgery, these data show that at least as many patients are seriously harmed,” he said. “These data tell us that we need to exercise caution when using beta blockers in this setting until we figure out how to mitigate the substantial risks and enable all patients to obtain the potential benefits of this intervention.”

Beta blockers work by slowing the heart rate and relaxing the blood vessels, which in turn reduces blood pressure. The problem, Devereaux said, is that during the period immediately after major noncardiac surgery (such as a hip or knee replacement, bowel resection or abdominal aortic aneurysm repair), patients are usually treated with opioid medications to relieve pain. The effects of those medications may mask drops in blood pressure or heart rate to dangerously low levels.

“Low blood pressure, or hypotension, is common in this setting and is a main contributor to the adverse effects resulting from perioperative beta blockers,” he said.

Patients who become hypotensive for whatever reason after surgery (e.g., sepsis, bleeding, heart failure) find their problem exacerbated when they are receiving a beta blocker, which further lowers blood pressure and makes treating hypotension more challenging.

The PeriOperative Ischemic Evaluation (POISE) trial enrolled 8,351 patients in 23 countries. Eligible patients were 45 years or older and had a history of heart disease, blood-vessel disease, stroke, congestive heart failure or other health problems such as diabetes or impaired kidney function. Patients’ median age was 69 and 63 percent were men.

Patients were randomly assigned to receive metoprolol or a placebo, beginning a few hours before surgery and for 30 days afterward. Patients, health care providers and research staff, except those analyzing data, were blinded to which group received metoprolol and which received a placebo. The study’s primary endpoint was a composite of the combined rate of death from heart disease, nonfatal heart attack and nonfatal cardiac arrest after 30 days.

At one-year follow-up, fewer patients in the metoprolol group than in the placebo group had heart attacks (5 percent vs. 6.2 percent), but more patients in the metoprolol group had died (9.8 percent vs. 8.5 percent in the placebo group) or had a stroke (2 percent vs. 1.4 percent in the placebo group).

These results followed the same pattern that had previously been seen at the 30-day follow-up: statistically fewer heart attacks in the metoprolol group (4.2 percent vs. 5.7 percent in the placebo group), but statistically more deaths (3.1 percent vs. 2.3 percent in the placebo group) and strokes (1 percent vs. 0.5 percent in the placebo group).

According to Devereaux, some observers have suggested that the metoprolol dose received by patients in the POISE trial (200 mg per day) was too high and that a lower dose would have produced fewer adverse effects. However, a lower dose might also have decreased the drug’s effectiveness in reducing heart attacks, he said, noting that the metoprolol dose in POISE only resulted in a seven beats per minute lower heart rate compared with placebo.

“I believe the answer is more continuous patient monitoring during the immediate post-surgical period so that dangerous drops in heart rate or blood pressure are promptly identified and treated,” he said.

Devereaux and his colleagues are currently conducting a study to test the effectiveness of remote automated patient monitors in reducing post-surgical cardiac complications.                

Links to all the ACC 2018 Late-Breaking Trials

For more information: www.acc.org

 

#ACC18

 

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the m
Overlay Init